Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
Please verify you are not a robot.